Indian drug-maker Panacea Biotec Ltd. has won tentative US FDA approval for its first-to-file ANDA for a generic version of Eli Lilly & Co.’s blood-thinner Effient (prasugrel). Now, to get the copycat prasugrel to the US market, Panacea is expanding an alliance with Apotex Inc., the largest Canadian-owned pharmaceutical company.
Under the agreement, the closely held Canadian firm will handle US sales and distribution of prasugrel in 5mg-to-10mg doses while...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

